Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

TNBC Paradigm Evolving With Intriguing Treatment Methods

November 14th 2019

Tiffany A. Traina, MD, discusses emerging therapies for the management of metastatic triple-negative breast cancer.

CDK4/6 Inhibitors Show Unmatched OS Benefit in Metastatic HR+ Breast Cancer

November 12th 2019

Komal Jhaveri, MD, FACP, discusses updates in research for metastatic HR-positive, HER2-negative breast cancer.

Prognostic and Predictive Assays Guide Therapy Decisions in Breast Cancer

November 11th 2019

Joseph A. Sparano, MD, discusses using gene expression profiles as a means to guide therapy in breast cancer.

Dr. Brufsky on Challenges in Breast Cancer Treatment

November 8th 2019

Adam M. Brufsky, MD, PhD, discusses remaining challenges in breast cancer.

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

November 1st 2019

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Dr. Domchek on Results of the MEDIOLA Trial in BRCA-Mutated Metastatic Breast Cancer

November 1st 2019

Susan Domchek, MD, discusses the results of the phase II MEDIOLA trial in germline BRCA-mutated metastatic breast cancer.

Early Adjuvant Chemotherapy Dose Reductions Correlate With Poorer Survival in Breast Cancer

October 31st 2019

Early dose reductions in a common adjuvant chemotherapy regimen were associated with inferior survival outcomes in a retrospective study of women with intermediate- to high-risk breast cancer.

Dr. Cristofanilli on Aromatase Inhibitor Adverse Events in Breast Cancer

October 30th 2019

Massimo Cristofanilli, MD, discusses adverse events caused by the use of aromatase inhibitors in breast cancer.

Eflapegrastim Application Resubmitted to FDA for Chemo-Induced Neutropenia

October 25th 2019

An updated biologics license application has been submitted to the FDA for eflapegrastim for the management of chemotherapy-induced neutropenia.

FDA Recommends Boxed Warning, Additional Labeling Measures for Breast Implants

October 23rd 2019

The FDA has issued a draft guidance to propose labeling recommendations, including a boxed warning, to breast implant manufacturers in an effort to help patients understand the benefits and risks of these devices.

Surgical Pioneer Flips the Script on Early Breast Cancer Treatment

October 21st 2019

Armando E. Giuliano, MD, a 2018 OncLive Giants of Cancer Care® award winner in Surgical Oncology, disrupted the treatment landscape for early breast cancer when he introduced sentinel lymph node biopsy. The result led to improved quality of life and reduced the need for radical breast cancer procedures for many patients.

Breast Cancer Pioneer, Giant of Cancer Care® Bernard Fisher Dies at 101

October 19th 2019

Bernard Fisher, MD, a world-renowned physician/scientist and the chair of the National Surgical Adjuvant Breast and Bowel Project for more than 27 years, has died at the age of 101.

Tracing Treatment Strategies in Early-Stage HR+/HER2- Breast Cancer

October 16th 2019

Gretchen G. Kimmick, MD, MS, discusses the management of patients with early-stage hormone receptor–positive, HER2-negative breast cancer.

Talking Tumors: Adaptive Approaches in Triple-Negative and HR-Positive Breast Cancers

October 16th 2019

In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.

Momentum for Change Builds in Recurrent Advanced Breast Cancer

October 16th 2019

New treatment approaches for patients with relapsed or refractory advanced breast cancer are making their way into clinical practice or are on the horizon.

Dr. Marcom on Liquid Biopsies in Breast Cancer

October 11th 2019

Paul Kelly Marcom, MD, discusses the use of liquid biopsies in breast cancer treatment.

Olaparib/Durvalumab Combo Shows Promising Long-Term Activity in Germline BRCA+ Breast, Ovarian Cancer

October 8th 2019

Updated results from the phase I/II MEDIOLA study strengthen the case for combining olaparib and durvalumab in patients with metastatic breast cancer and relapsed ovarian cancer with germline BRCA mutations. The updated data were featured in two separate presentations at the 2019 ESMO Congress.

Immunotherapy for Breast Cancer: What's New and What's on the Horizon?

October 7th 2019

Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.

Earlier Diagnosis and Treatment Are Next Steps in TNBC Paradigm

October 7th 2019

There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.

Dr. Osborne on Evaluating HER2 Positivity in Breast Cancer

October 7th 2019

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.